INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Aldeyra Therapeutics, Inc. following a significant stock price drop after the FDA's response regarding their investigational drug candidate reproxalap [1][2]. Group 1: Company Overview - Aldeyra Therapeutics, Inc. is focused on developing reproxalap for the treatment of dry eye disease [2]. - The company received a Complete Response Letter from the FDA indicating that the New Drug Application (NDA) for reproxalap did not demonstrate adequate efficacy [2]. Group 2: FDA Response and Stock Impact - The FDA's Complete Response Letter highlighted that no manufacturing or safety issues were found, but the NDA failed to show efficacy in well-controlled studies [2]. - Following the FDA's announcement, Aldeyra's stock price plummeted by $3.90, a decrease of 73.31%, closing at $1.42 per share on April 3, 2025 [2]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud by Aldeyra and its officers or directors [1]. - The firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3].